Updated from 1:50 p.m. EST with new stock pricesSmall-cap stocks jumped ahead of the broader market Tuesday, spending some time in positive territory even as the major indices remained in the red. PetMed Express ( PETS - Get Report), a vendor of medication for pets, jumped 21.2% to $13.30 on a rise in fiscal third-quarter earnings. The Pompano Beach, Fla.-based company reported income of $4.4 million, or 18 cents a share, vs. $2.8 million, or 11 cents a share, in the year-ago quarter. Analysts polled by Thomson Financial were expecting 14 cents a share. Meanwhile, Seattle-based Getty Images ( GYI), jumped 12.9% to $24.78 on news that the creator and distributor of visual content had hired Goldman Sachs to review its strategy and help it explore strategic alternatives to enhance shareholder value. On the losing side, Corinthian College ( COCO), a post-secondary education company, saw shares fall 30.7% to $7.55 on its announcement that reductions in loans for students with higher credit risk would reduce earnings. The Santa Ana, Calif.-based company cut 2008 earnings guidance to the lower end of its previous range of 40 to 45 cents a share. Gun maker Smith & Wesson ( SWHC) dropped 20.5% to $4.00. Citing "an uncertain business environment," CEO Michael Golden announced the Springfield, Mass., company had suspended providing financial guidance for its fiscal 2008 ending April 30. Also falling was Twin Disc ( TWIN - Get Report), a Racine, Wis., maker of off-highway power transmission equipment. For the second quarter of its fiscal 2008, Twin Disc posted earnings of $4.2 million, or 37 cents a share, down from $5.7 million, or 48 cent a share, in 2007. Shares sank 26.8% to $16.36. More broadly, the Russell 2000 inched down a slight 0.2% to 671.57, and the S&P SmallCap 600 lost 0.02% to 350.52.
More from Investing
Top 5 Stock Winners in Dow Jones Industrial Average This Week
The Dow Jones Industrial Average finished Friday above 28000 for the first time ever. Here are the top 5 winning stocks in the Dow from this week.
Why Stock Charts Are a More Valuable Tool Than Ever
What I have found is that the real value of charts is as a trade management tool.
Novartis Still a Buy Despite Controversy Over Blockbuster Drug
Despite the issues that have bubbled up related to its breakthrough drug for spinal muscular atrophy, Zolgensma, Novartis "has the newest pipeline with many drugs just beginning to have an impact on the company's bottom line," Cramer told members of his Action Alerts PLUS club for investors during an exclusive video-conference call.
Could Netflix Survive on Just Its Own Original Content?
Netflix says that viewers shell out for original shows like Stranger Things and Orange is the New Black -- but production costs have ballooned roughly 30% since last year, which has many investors spooked.